Adamas Pharmaceuticals, Inc. (ADMS) financial statements (2020 and earlier)

Company profile

Business Address 1900 POWELL ST., SUITE 1000
EMERYVILLE, CA 94608
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:150211176136120122
Cash and cash equivalents725791243361
Short-term investments7815482907461
Other undisclosed cash, cash equivalents, and short-term investments  32213 
Receivables661161
Inventory, net of allowances, customer advances and progress billings552   
Inventory552   
Prepaid expense 33110
Other current assets 10100
Other undisclosed current assets62(3)(22)(13)0
Total current assets:167228179117113124
Noncurrent Assets
Property, plant and equipment343321
Long-term investments and receivables  3221336
Long-term investments  3221336
Other noncurrent assets  1000
Other undisclosed noncurrent assets103    
Total noncurrent assets:1367251638
TOTAL ASSETS:180235186142129161
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities23241691219
Accounts payable774434
Accrued liabilities161712689
Employee-related liabilities     2
Taxes payable     5
Debt2     
Other liabilities210000
Other undisclosed current liabilities     (7)
Total current liabilities:262417101213
Noncurrent Liabilities
Long-term debt and lease obligation124117103   
Long-term debt, excluding current maturities124117103   
Liabilities, other than long-term debt231112
Other liabilities231112
Other undisclosed noncurrent liabilities9     
Total noncurrent liabilities:134121103112
Total liabilities:161145120101314
Stockholders' equity
Stockholders' equity attributable to parent209066132116147
Common stock000000
Additional paid in capital444433278255178158
Accumulated other comprehensive income (loss)0(0)(0)(0)(0)(0)
Accumulated deficit(425)(343)(212)(122)(62)(10)
Total stockholders' equity:209066132116147
TOTAL LIABILITIES AND EQUITY:180235186142129161

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues133411256
Revenue, net1   
Cost of revenue
(Cost of Goods and Services Sold)
(2)(1)(0)   
Gross profit:113311256
Operating expenses(147)(148)(88)(62)(59)(37)
Other undisclosed operating income38 0   
Operating income (loss):(98)(115)(88)(61)(57)19
Nonoperating expense
(Investment Income, Nonoperating)
     (1)
Interest and debt expense(15)(19)(5)   
Other undisclosed income from continuing operations before equity method investments, income taxes031100
Income (loss) from continuing operations before income taxes:(113)(131)(91)(60)(57)18
Income tax expense (benefit)  205(7)
Net income (loss):(113)(131)(89)(60)(52)10
Other undisclosed net income attributable to parent2     
Net income (loss) attributable to parent:(111)(131)(89)(60)(52)10
Preferred stock dividends and other adjustments     (0)
Other undisclosed net loss available to common stockholders, basic     (1)
Net income (loss) available to common stockholders, basic:(111)(131)(89)(60)(52)9
Dilutive securities, effect on basic earnings per share     0
Net income (loss) available to common stockholders, diluted:(111)(131)(89)(60)(52)9

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net income (loss):(113)(131)(89)(60)(52)10
Comprehensive income (loss):(113)(131)(89)(60)(52)10
Other undisclosed comprehensive income (loss), net of tax, attributable to parent2(0)0(0)0(0)
Comprehensive income (loss), net of tax, attributable to parent:(110)(131)(89)(60)(52)10

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: